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Virion-associated peptidoglycan hydrolases (VAPGH) are phage-encoded lytic 
enzymes that locally degrade the peptidoglycan (PG) of the bacterial cell wall during 
infection. In contrast to endolysins, PGHs that mediate lysis of the host bacteria at the 
end of the lytic cycle to release of phage progeny, the action of VAPGHs generates a 
small hole through which the phage tail tube crosses the cell envelope to eject the phage 
genetic material at the beginning to the infection cycle. The antimicrobial activity of 
VAPGHs was first discovered through the observation of the phenomenon of ‘lysis 
from without’, in which the disruption of the bacterial cell wall occurs prior to phage 
production and is caused by a high number of phages adsorbed onto the cell surface. 
Based on a unique combination of properties of VAPGHs such as high specificity, 
remarkable thermostability, and a modular organization, these proteins are potential 
candidates as new antibacterial agents, e. g. against antibiotic resistant bacteria in 
human therapy and veterinary as well as biopreservatives in food safety, and as 
biocontrol agents of harmful bacteria in agriculture. This review provides an overview 





Bacteriophages (phages) are viruses that exclusively infect bacteria. They are 
widespread throughout nature and during their lytic life cycle kill their hosts. Interest in 
using bacteriophages as antimicrobial agents has increased in recent years due to the 
high incidence of antibiotic-resistant bacteria. Several reports have indicated the 
effectiveness of bacteriophages against pathogenic bacteria causing infections in 
animals or humans via phage therapy (Lu and Koeris, 2011). More recently, the 
potential applications of bacteriophages have been extended to other fields such as food 
safety which seeks to prevent contamination of food (biocontrol) (García et al., 2008; 
Mahony et al., 2011). Bacteriophages can also be used as tools for detecting pathogens 
in foods or the environment, for disinfection of medical tools and devices, to prevent 
formation of bacterial biofilms on industrial surfaces or as drug delivery vehicles (for a 
recent review see Courchesne et al., 2009). 
In addition to bacteriophages, phage lytic proteins also provide successful 
elimination of pathogenic bacteria (Fischetti, 2010). There are two general classes of 
phage lytic proteins, which mediate the enzymatic cleavage of PG: endolysins and 
VAPGHs. These proteins exert their action at different steps of the infection cycle. 
VAPGHs act in the first step of the phage lytic cycle (Fig. 1) degrading the PG to allow 
the phage infection. Their action occurs prior to the transport of phage genetic material 
across the bacterial cell envelope (Letellier et al. 1999). They seem to be quite common 
in bacteriophages infecting both Gram-negative and Gram-positive bacteria as shown by 
zymograms of fully assembled virions and by homology analysis of sequenced 
phage/prophage genomes (Moak and Molineux, 2004). Endolysins are produced during 
the late phase of gene expression in the lytic cycle and are responsible for the progeny 
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phage release (Young et al., 2000). Their bacteriolytic activity when added exogenously 
to Gram positive bacteria has triggered intense study in the recent years (for review see 
Fischetti, 2010). Indeed, their potential to control pathogens on mucosal surfaces and 
systemic infections has been reviewed recently (Fenton et al., 2010), as well as in food 
control and as tools for pathogen detection (reviewed by Callewaert et al., 2011).  
The presence of virion-associated muralytic activities has been detected in 
numerous bacteriophages (Table 1), but only a few labs have further sub-cloned, 
purified, and demonstrated the antimicrobial activity of the responsible proteins in vitro. 
Given the previous success of endolysins as antimicrobial agents and the steadily 
increasing prevalence of antibiotic resistant bacteria, it is worthwhile to study the 
antimicrobial potential of these proteins. In fact, both bacteriophages and bacteriophage-
encoded proteins with antimicrobial activity represent a promising alternative to 
antibiotics, as potential new antimicrobials against infectious diseases (Matsuzaki et al., 
2005; Fischetti et al., 2010). 
 
Virion-associated muralytic activities are present in phages infecting Gram-
negative and Gram-positive bacteria. 
Early evidence of muralytic enzymes associated with bacteriophages infecting 
Gram-negative bacteria were found in particles of the membrane encapsulated 
bacteriophage Φ6 which infects Pseudomonas syringae. It was demonstrated that the 
virion associated protein P5, digests the PG to allow penetration of the viral core into 
the host, and also serves as an endolysin to allow release of the phage from the host 
(Mindich and Lehman, 1979). Later it was postulated that gp5, a structural baseplate 
protein of phage T4, was required for ‘lysis from without’. Mutations in this protein 
yielded phages with a reduced ability to cause ‘lysis from without’ following heat 
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treatment of the phage, while heating had no effect on the ability of the wild-type 
phages to lyse from without (Kao and McClain, 1980). Recently, it has been 
demonstrated that phage T4 penetrates the outer membrane of E. coli using a 
multifunctional device composed by the gp5 protein trimer that first ‘drills’ a hole in the 
outer membrane, and with its lysozyme domain further degrades the PG layer enlarging 
the initial hole, allowing the DNA to be injected (Nishima et al., 2011).  
Other phages infecting E. coli such as phage T7, also displayed muralytic 
activity associated with their virions. Mutations in the catalytic domain of the internal 
phage capsid protein lytic transglycosylase, gp16, were associated with a failure in the 
translocation of DNA into the cell cytoplasm when the host growth conditions resulted 
in a highly cross-linked PG (Moak and Molineux, 2000). Moreover, zymograms of 
these virions containing mutations in gp16 did not reveal any muralytic activity (Moak 
and Molineux, 2004). Similarly, zymogram analysis and N-terminal sequencing 
revealed the presence of a PG hydrolase (PGH) (gp4) in phage P22 infecting Salmonella 
typhimurium, which is also an internal head protein. Viral particles lacking gp4 were 
unable to show PGH activity (Moak and Molineux, 2004). Furthermore, the straight 
fiber Pb2 from phage T5 also carries muralytic activity. It is involved in DNA transfer 
into the host and is able to cause both galactosidase release from E. coli cells and in 
vitro PG hydrolysis (Boulanger et al., 2008). The broad-host-range phage PRD1 also 
harbors a transglycosylase domain included in the amino-terminus of protein P7. This 
was demonstrated by zymogram analysis of wild-type PRD1 and various mutant phage 
particles. P7 protein is postulated to be involved in DNA entry as both DNA replication 
and host cell lysis were delayed in its absence (Rydman and Bamford, 2000). Phage 
PRD1 encodes another structural protein (P15) with glycosidase activity, which is a 
soluble 1,4-N-acetylmuramidase that causes phage-induced host cell lysis. The 
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incorporation of these two unique lytic activities enzymes into virions may in part be 
responsible for or support the broad host range of bacteriophage PRD1 (Rydman and 
Bramford, 2002).  
Regarding phages infecting other species such as the Pseudoalteromonas PM2 
phage, it was demonstrated that the P7 protein, one of the components of the internal 
viral lipid core particle, has bacteriolytic activity. This protein is involved in the PG 
penetration process and causes a limited depolarization of the cytoplasmic membrane 
(Kivela et al., 2004). A similar phenomenon was also observed in P. syringae phage 
Φ13, which contains a thermosensitive lytic enzyme involved in PG penetration 
(Daugelavicious et al., 2005). Phages ΦKMV and ΦKZ infecting Pseudomonas 
aeruginosa strains also displayed structural proteins with PG hydrolase domains (Briers 
et al., 2006, 2008). Of note, the VAPGH gp36 from bacteriophage ΦKMV showed high 
thermoresistance. It has been postulated that this property is related to the location of 
this protein as part of the extensible tail from which it is ejected in an unfolded state 
during phage infection (Briers et al., 2006). Heat stability is not only a recurring 
property of structural lysins, but of any structural phage protein (Lavigne et al., 2004; 
Briers et al., 2006; Rodríguez et al., 2011).  
 From a limited screening of public data sets, PGH activities appear to be a 
frequent property of phages infecting Gram-positive bacteria (Nelson et al., 2012). 
Initially, VAPGH activities were described by zymogram analysis in phages sk1, r1t 
and c2 infecting Lactococcus lactis, and in phage phi11 infecting Staphylococcus 
aureus (Moak and Molineux, 2004). However, no further reports were published about 
the characterization of these proteins. In Bacillus subtilis SP-β prophage, zymogram 
analysis of purified particles showed a degradation band corresponding to the PGH 
CwlP (Moak and Molineux, 2004). The activity of this protein was later analyzed by 
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reverse phase (RP)-HPLC and mass spectrometry revealing the presence of two 
domains, muramidase and endopeptidase. Both domains were able to hydrolyze PG and 
cell walls of B. subtilis (Sudiarta et al. 2010). Φ29, another B. subtilis phage, showed 
PG hydrolytic activity of the DNA terminal protein gp3 by zymogram analysis (Moak 
and Molineux, 2004). An in-depth characterization of the tail-associated protein 
(Tal2009) from the L. lactis phage Tuc2009 was performed. Tal2009 belongs to the M37 
protein family and it was determined to be located at the tail tip where it is essential to 
mediate the host infection (Kenny et al., 2004). Additional work was carried out on S. 
aureus phages P68, phiMR11 and phiIPLA88. Unlike other VAPGHs, protein 17 from 
phage P68 has a C-terminal region required for binding to the cell surface, while the N-
terminus comprises the muralytic activity domain. A putative role in the infection 
process was deduced for this protein due to its ability to prematurely lyse S. aureus cells 
when added exogenously (Takac and Blasi, 2005). The presence of two active catalytic 
domains, CHAP (cysteine, histidine-dependent amidohydrolases/peptidase) (Bateman 
and Rawlings, 2003) and LYZ2 (lysozyme subfamily 2) (Rashel et al., 2008), was 
shown in gp61 from phiMR11. Gp61 has been localized to the tail tip of the phage by 
immuno-electron microscopy. Due the tail tip seems to be the first part of 
bacteriophages to contact directly the bacterial surface, this might indicate that this 
protein is involved in ‘‘lysis from without’’ (Rashel et al., 2008). A similar structure 
with those two catalytic domains was also identified in HydH5, the VAPGH from 
phiIPLA88.  The high thermostability of HydH5 is remarkable, which retained activity 
after 5 min at 100°C (Rodríguez et al., 2011). 
 
Putative role of the virion-associated muralytic enzymes in the phage infection 
cycle. 
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Although all the findings suggest a role of the VAPGH proteins in the first step 
of the infection cycle, there is still room for more definitive studies. Most authors 
speculate about the position of these proteins and the need to disrupt the PG layer to 
allow the tail tube to penetrate the cell wall. The most extensive work about tail 
structure and its involvement in the infection process is from the widely studied phage 
T4 (Leiman et al., 2010). This elegant work supports the hypothesis that the VAPGHs 
are involved in degrading the PG during infection, and explains how the conformational 
change of the baseplate and the tail contraction are related to the tail’s host cell 
recognition and membrane penetration function. In this process, the full activity of gp5 
lysozyme is not essential for infection because even partial lysozyme activity can digest 
the small (but sufficient) portion of the cell wall to permit the tail tube to penetrate 
(Kanamaru et al., 2005).  
On the other hand, the contraction of the tail structure is not possible in 
Siphoviridae phages, and no reported data exists to explain the mechanism of DNA 
ejection into the cell. However, evidence of the role of these proteins was obtained from 
the siphovirus Tuc2009 phage where infection was reduced by 100-fold in the presence 
of antibodies against Tal2009 (Kenny et al., 2004). This phenomenon is further supported 
by the demonstration that the gp16 transglycosylase activity of Podoviridae 
bacteriophage T7 is not essential for phage growth, but was  beneficial during infection 
of E. coli under conditions when the murein is more highly cross-linked (e.g. cells 
grown to high cell density or under low temperature conditions) (Moak and Molineux, 
2000). These authors suggest that cells growing exponentially displayed a sufficiently 
porous PG to allow the phage tail tube proteins to pass through the mesh of glycan 
strands and peptide cross-links. In contrast, under conditions of high density or low 
temperature, the PG becomes multilayered and the porosity of the murein reduced, 
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necessitating a PG degrading activity to achieve a high infection efficiency.  It should 
not be misconstrued that the phage must rely on VAPGHs to have a successful 
infection. In fact, it is not in the best interest of the phage that the VAPGHs degrade the 
PG too efficiently, because the cell has to be sufficiently stable and survive long enough 
to allow phage propagation. Along these same lines, it should also be mentioned that the 
host bacteria also initiates a cell wall restoration effort immediately after phage 
infection. Recent studies in Lactococcus lactis subsp. lactis IL1403 at an early stage of 
infection with the lytic phage c2 have shown a global molecular response strongly 
targeted to the cell wall. Induction of membrane stress proteins, D-alanylation of cell 
wall lipoteichoic acids (LTAs), and maintenance of the proton motive force (PMF) are 
all  triggered after phage infection presumably  to restore cell wall stability (Fallico et 
al., 2011).  
On the other hand, there are also examples of phage-induced mechanisms that 
favourably alter the PG to promote the phage infection success but they are induced late 
in the infection cycle.  For instance, the Streptococcus pneumoniae autolysin LytA is 
activated at the end of the phage lytic cycle by the holin-induced membrane 
permeabilization. The activation of autolysin LytA, together with the phage endolysin, 
leads to greater phage progeny release (Frias et al., 2009).  
 
Antimicrobial activity of purified VAPGHs. 
”Lysis from without” could theoretically be observed for all bacteria infected by 
phages containing VAPGHs. However, to observe this phenomenon, a high multiplicity 
of infection is likely required [a phage/bacteria ratio >100 and a high phage titer (≥109 
phages/ml) has been suggested by Stephen Abedon (Abedon, 2011) and L.M. Kasman 
(Kasman et al., 2002)] although not all phages have been demonstrated to be capable of 
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causing lysis from without and the numbers of phages required per cell to elicit this 
effect are not clear and likely highly variable depending on the host. 
It should be noted that the rate at which phage adsorb to bacteria is a function of 
phage density, whereas the total number of phages adsorbed to a bacterium is a function 
of both the phage/bacteria ratio as well as the inherent capacity of bacterium to adsorb 
the phage (Abedon, 2011). 
Evidence that lytic activity of virions can be due to specific virion-associated 
proteins was obtained after purification and subsequent exposure of viable bacteria to 
these proteins. HydH5 from phiIPLA88 showed the highest antimicrobial activity 
against early exponential S. aureus cells at 45°C and in the absence of divalent cations 
(Rodríguez et al., 2011). Similar challenge assays also showed lytic activity against S. 
aureus by both catalytic domains from phiMR11 gp61 (Rashel et al., 2008). Similarly, 
phage P68 protein 17 displayed activity against clinical S. aureus isolates, including 
methicillin-resistant strains (Takac and Blasi, 2005).  
Regarding the antimicrobial activity of PGHs (endolysins and VAPGHs) against 
Gram negative bacteria, it is worth noting that the presence of the outer membrane is a 
barrier that these proteins must overcome to reach the PG substrate. Despite this hurdle, 
the lytic activity of VAPGHs against these bacteria has been confirmed after 
destabilization of the outer membrane by incubation of the cells in chloroform-saturated 
buffer at room temperature. Most of the VAPGH studies in Gram negative infecting 
phages have studied Pseudomonas phages. It was shown that the phage ф6 P5 protein is 
active against several Gram negative bacteria (Pseudomonas phaseolicola, P. 
aeruginosa, Pseudomonas fluorescens, Pseudomonas putida, E. coli, Salmonella 
typhimurium and Proteus vulgaris) under these outer membrane destabilizing 
conditions, but no activity was detected against Gram positive species. This protein is a 
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thermosensitive endopeptidase which cleaves the peptide bridge formed between meso-
diaminopimelic acid and D-alanine (Caldentey and Bamford, 1992). The VAPGH from 
phage ΦKZ, Gp181, also has a wide lytic spectrum including seven Gram-negative 
species (P. aeruginosa, P. fluorescens, P. putida, E. coli, S. typhimurium, Burkholderia 
solanacearum, and Yersinia enterocolitica). In addition, this protein tolerates a high 
ionic strength and is not very sensitive to long thermal treatments. Finally, the presence 
of a lysozyme activity in the ΦKMV phage particle, named gp36, was also verified on 
chloroform-treated P. aeruginosa PAO1 and E. coli WK6 cells. It is highly 
thermostable, retaining 26% activity after 2 h at 100°C and 21% after autoclaving 
(Lavigne et al., 2004). These properties are interesting for applications as enzybiotics 
and to be included as part of food safety technology (Briers et al., 2008). 
Antimicrobial activity of VAPGHs can be improved by domain swapping or by 
synergy with other antimicrobials. Toward this end, a chimeric protein (P16-17) 
harbouring the endopeptidase domain of P68 endolysin (Lys16) and the C-terminal cell-
wall binding domain of phage P68 protein 17 reduced the required effective dose of 
gentamicin towards clinical S. aureus strains (Manoharadas and Blasi, 2009). Similarly, 
a substantial increase in the lytic activity of some PGH domains was observed by fusion 
to staphylococcal cell-wall binding domains. The CHAP domain from a tail-associated 
muralytic enzyme from phage K was fused to the lysostaphin SH3 cell-wall binding 
domain generating protein P128 with a potent anti-staphylococcal activity. It was shown 
that concentrations ≥ 2.5 μg/ml killed 99.9% of 108 CFU/ml in an in vitro challenge. 
Moreover, staphylococcal colonization of rat nares with ~109 CFU  was reduced by two 
orders of magnitude with twice daily treatments of P128 (100 μg) (Paul et al., 2011). 
Likewise, a P128 hydrogel formulation was bactericidal against staphylococci 
[including S. aureus] recovered from the nares of 31 healthy patients (Vipra et al., 
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2012). Similarly, the CHAP domain from HydH5 phiIPLA88 increased its lytic activity 
by fusion to lysostaphin SH3 domain and even displayed antimicrobial synergy with the 
endolysin LysH5 in vitro (Rodríguez-Rubio et al., 2012a). The domain swapping 
approach has also proven to be useful for the improvement of endolysin activity 
(Manoharadas and Blasi, 2009). 
 
Evolutionary insights 
As mentioned before, the dominant feature of phage lytic proteins, endolysins 
and VAPGHs, is their extraordinary similarity in amino acid sequence and protein 
structure. Previously, it was noted that pneumococcal phage endolysins showed a 
modular structure based in catalytic domains like bacterial autolysins (López and 
García, 2004). More recently, computer-based analysis of VAPGHs amino acids 
sequences from different phages infecting S. aureus revealed a high similarity between 
these proteins (Rodríguez et al., 2011). Moreover, endolysins encoded by 
staphylococcal phages, and particularly the CHAP domain, presented a conserved 
sequence also found in bacterial PG hydrolytic proteins (Zou and Hou, 2010). This 
would not be surprising because they all share the same PG substrate. In addition, the 
similarity between VAPGHs, phage endolysins, and bacterial autolysins supports the 
so-called ‘moron accretion hypothesis’ for the origin of phage suggesting that 
bacteriophages have evolved by recombinational reassortment of genes and by the 
acquisition of novel genetic elements (Hendrix et al., 2000).  
In contrast to this similarity, there is a notorious difference in protein structure. 
VAPGHs described to date do not have an identifiable cell wall binding domain (CBD) 
as do endolysins. VAPGHs, in contrast to endolysins, might not require a CBD because 
they are “delivered” to the PG substrate in large part by the virion particle structure.  
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For some bacteriophages  PG-hydrolysing domains have been observed in the 
tape measure proteins (TMPs) rather than VAPGHs (Fraser et al., 2007; Rodríguez-
Rubio et al., 2012b), which suggests they might be involved in infection and DNA 
ejection into stationary phase cells (Piuri and Hatfull, 2006). In fact, a growing number 
of conserved domains are being recognized in other phage structural proteins that 
probably play roles in attachment to host cells through sugar binding or degradation of 
the polysaccharides on the cell surface (Fraser et al., 2007).  
The abundance of PG-degrading activities associated with phage particles, either 
as individual proteins or as catalytic domains included in other proteins, raises an 
important question about whether or not they are essential to the infection process. To 
date, it has not been possible to demonstrate that these proteins are essential for phage 
infection except under certain culture conditions that result in high PG cross-linking 
(Moak and Molineux, 2004). Although these conditions (low temperature or high 
bacterial density) might not generate PG that is representative of host cells grown under 
optimized laboratory conditions, these conditions might generate PG that better reflects 
growth of the host in some naturally occurring environments, suggesting that phages 
might gain a selective advantage by adding these PG hydrolytic activities to their virion 
surfaces.  
 
Prospects for the use of purified VAPGHs. 
 The knowledge of the molecular biology of bacteriophages has allowed us to 
develop new weapons to prevent and combat unwanted bacterial growth (Fischetti, 
2010; Clark and March, 2006). Moreover, since bacteriophages are the most abundant 
biological entities on earth, they constitute a natural source of information to design 
new phages and proteins (Lu and Collins, 2007; Lukacik et al., 2012). Bacteriophage 
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lytic proteins and specifically VAPGHs have several characteristics which make them 
suitable for their application as antimicrobials: 
a) Mode of action: Due to the high degree of catalytic domain similarity at the amino 
acid level, both endolysins and VAPGHs are believed to share a similar mode of action 
hydrolyzing specific bonds in PG structure. It is reported that during co-evolution of 
phage and host, these phage lytic proteins have found unique and highly conserved 
bonds, modification of which is rare, thus, resistance to these proteins is a very rare 
event. To date, bacterial resistance development to phage lytic proteins has only been 
tested with endolysins but no resistance has been reported (Fischetti, 2005). Therefore, a 
similar result is expected for VAPGHs.  
b) High specificity: Most bacteriophage lytic proteins demonstrate near-species or –
genus specificity, to the host species/genus of the phage from which the lytic protein is 
derived (Zimmer et al., 2002; Rodriguez-Rubio et al., 2012). However, there are 
exceptions, for example, an enterococcal phage lysin PlyV12 can not only kill 
enterococci but also several other Gram-positive pathogens, such as Streptococcus 
pyogenes, group B streptococci and Staphylococcus aureus (Yoong et al., 2004). 
Similarly, a lysin from Lactobacillus casei bacteriophage A2, was described with a 
wide lytic spectrum (Ribelles et al., 2012). Regarding VAPGHs, those derived from 
Gram negative infecting phages seem to have wider lytic spectrum (see above). In 
contrast, VAPGHs from Gram positive infecting phages have thus far demonstrated 
specificity limited to species/genus of the host species. Although this near-species 
specificity is not optimal when considering mixed-pathogen infections, it is a property 
that provides a clear advantage over broad range antibiotics in the context of resistance 
development. Broad range antimicrobials lead to selection for resistant strains not just in 
the target pathogen, but also in co-resident commensal bacteria that are exposed to the 
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drug.  The acquisition of antibiotic resistance is often accomplished by transfer of DNA 
sequences (genomic or plasmid sources) from a resistant strain to a susceptible strain.  
This transfer is not necessarily species or genus limited, and it can lead to commensal 
bacteria that are both antibiotic resistant and that can serve as carriers of these DNA 
elements for propagation to neighboring bacteria. Those neighboring strains (potential 
pathogens) with newly acquired resistance elements can emerge as antibiotic resistant 
strains during future treatment episodes. Thus, in order to reduce the spread of antibiotic 
resistance, it is recommended to avoid subjecting commensal bacterial communities to 
broad range antibiotics. Toward this end, FDA, USDA, and CDC promote the 
development of antimicrobials that reduce the risk of resistance development (CDC 
Action Plan: http://www.cdc.gov/ drugresistance/actionplan/html/product.htm).    
c) Effective on drug-resistant strains: VAPGHs are effective even against antibiotic 
resistant bacteria (Paul et al., 2011; Rodríguez-Rubio et al., 2012a), a major advantage 
taking into account the increasing frequency of multi-drug resistant strains.  
d) Thermostability: A remarkable number of VAPGHs are highly thermostable, 
retaining activity after high temperature treatments similar to those used in food 
technology. This property might be exploited in the improvement of food safety by 
implementation of these proteins in combination with other preservation approaches 
(e.g. pasteurization), to ensure the microbial safety as well as the organoleptic and 
nutritional quality of food products (hurdle technology).  
e) Modular organization: VAPGHs described to date have a modular organization 
with one or two catalytic domains, similar to endolysins (Hermoso et al., 2007), which 
allows engineered domain swapping in order to improve their lytic activity (Rodríguez-
Rubio et al., 2012a), but more importantly, multiple lytic domains are expected to 
reduce the likelihood of resistant strain development (Fischetti, 2005) 
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 The potential applications of VAPGHs include human therapy as well as food 
safety, veterinary and agriculture. In the food industry, VAPGHs might be used as 
biopreservatives to avoid the spoilage and food safety concerns related to pathogenic 
bacterial growth in food (García et al., 2010). VAPGHs application as surface 
disinfectants could help to sterilize food equipment surfaces where pathogens are able to 
form biofilms which are highly resistant to cleaning and disinfection routine (Sharma 
and Anand, 2002). It is well known that food handlers are an important focus of 
bacterial contamination in the food chain (Wattinger et al., 2012). In this regard, 
decontamination of asymptomatic food handlers by VAPGHs could be considered. 
Similarly, there is a need for non-antibiotic antimicrobials in animal health due to the 
phasing-out of antibiotics in farm animals for nonmedical purposes 
(http://ec.europa.eu/health/antimicrobial_resistance/policy/index_en.html). There was a 
recent US court order supporting a similar restriction on the use of some antibiotics  
such as penicillin and tetracycline to promote growth in animals 
(http://www.nytimes.com/2012/03/24/health/fda-is-ordered-to-restrict-use-of-
antibiotics-in-livestock.html) that is still under debate at the US Food and Drug 
Administration. VAPGHs could represent an alternative in the treatment and 
prophylaxis of infectious diseases, similarly to that proposed for phage endolysins 
(Fenton et al., 2010). These lytic enzymes might also play a role in agriculture to 
exclude the use of synthetic chemicals in the control and elimination of 
phytopathogenic bacteria (During et al., 1993).  
 
Conclusion 
Phage encoded PGH proteins, endolysins and VAPGHs, have a remarkable potential as 
novel bacteriolytic antimicrobials to combat antibiotic-resistant bacteria. This is 
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especially true when considering that an extracellular site of action avoids many of the 
intracellular resistance mechanisms that bacteria have evolved to combat conventional 
broad-range antibiotics (e.g. efflux pumps).  Previous studies with phage endolysins, 
which share protein structure and mode of action with VAPGHs, support their potential 
use to combat infectious diseases in animal models and in the biocontrol of numerous 
pathogenic species. In this context, VAPGHs provide a new source of lytic enzymes. 
Noteworthy is the thermoresistance observed for some of this class of enzymes, which 
might find application in novel biotechnological settings (e.g. pasteurization). In light of 
the promising results reported from the limited number of VAPGHs that have been 
examined for their antimicrobial properties, this is an area of phage biology that 
deserves a much more concerted effort.   
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Figure 1. Mode of action of virion-associated PG hydrolases (VAPGHs).  
 
 
